

Contents

Preface *XI*

List of Contributors *XIII*

- 1 Ubiquitin Signaling and Cancer Pathogenesis 1**
Kaisa Haglund and Ivan Dikic
 - 1.1 Introduction 1
 - 1.1.1 Ubiquitin Signaling Networks 3
 - 1.1.2 Ubiquitin-like Proteins 4
 - 1.2 Ubiquitin in Cancer Pathogenesis 5
 - 1.2.1 Ubiquitin in Cell Cycle Control 5
 - 1.2.2 Ubiquitin in the NF- κ B Pathway 8
 - 1.2.3 Ubiquitin as a Signal in DNA Repair 9
 - 1.2.3.1 p53 Pathway 9
 - 1.2.3.2 BRCA1 and FANCD2 10
 - 1.2.3.3 PCNA and TLS Polymerases 11
 - 1.2.4 Ubiquitin Networks in Angiogenesis 11
 - 1.2.5 Ubiquitin Networks in Receptor Endocytosis 12
 - 1.3 Targeting Ubiquitin Networks in Cancers 13
 - 1.3.1 Targeting Interactions between E3s and their Substrates 13
 - 1.3.2 Targeting the Proteasome 14
 - 1.3.3 Other Approaches 14
 - 1.4 Conclusions and Future Perspectives 15
- 2 Regulation of the p53 Tumor-suppressor Protein by Ubiquitin and Ubiquitin-like Molecules 21**
Dimitris P. Xirodimas
 - 2.1 Functional Domains of p53 21
 - 2.2 The Family of Ubiquitin-like Molecules 22
 - 2.3 E3 Ligases for p53 23
 - 2.4 Modification of p53 with Ubiquitin 25
 - 2.5 Requirements for Mdm2-mediated Ubiquitination of p53 26
 - 2.6 Regulation of p53 Ubiquitination 28
 - 2.6.1 E2 Conjugating Enzymes 28

2.6.2	Interacting Proteins	29
2.6.3	By Other Post-translational Modifications	31
2.7	De-ubiquitination of p53	32
2.8	SUMO-1/sentrin/smpt3	33
2.9	NEDD8/Rub1	33
2.10	Therapeutic Intervention through the Ubiquitin Pathway	34
3	The Ubiquitin-Proteasome System in Epstein-Barr Virus Infection and Oncogenesis	47
	<i>Maria G. Masucci</i>	
3.1	Introduction	47
3.2	Viral Interference with the Ubiquitin-Proteasome System	47
3.3	The EBV Life Cycle	50
3.4	EBV and the Ubiquitin-Proteasome System	52
3.4.1	EBNA1	52
3.4.2	EBNA6 (EBNA3C)	56
3.4.3	LMP1	57
3.4.4	LMP2	59
3.4.5	BZLF1 (Zta) and BRLF1 (Rta)	61
3.4.6	BPLF1	62
3.5	EBV-associated Malignancies	63
3.6	Concluding Remarks	65
4	HECT Ubiquitin-protein Ligases in Human Disease	77
	<i>Martin Scheffner and Olivier Staub</i>	
4.1	Introduction	77
4.2	Definition of HECT E3s	77
4.3	Human HECT E3s and their Role in Disease	79
4.4	E6-AP	80
4.4.1	E6-AP and Cervical Cancer (Cancer of the Uterine Cervix)	80
4.4.2	E6-AP and Angelman Syndrome	83
4.5	HECTH9	84
4.6	HECT E3s with WW Domains	85
4.6.1	Nedd4/Nedd4-2	86
4.6.1.1	Nedd4/Nedd4-2 and Liddle's Syndrome	86
4.6.1.2	Nedd4 and Retrovirus Budding	88
4.6.2	Itch and the Immune Response	88
4.6.3	Smurfs	91
4.6.3.1	Smurfs and Cancer	93
4.6.3.2	Smurfs and Bone Homeostasis	94
4.7	Concluding Remarks	95
5	Ubiquitin-independent Mechanisms of Substrate Recognition and Degradation by the Proteasome	107
	<i>Martin A. Hoyt and Philip Coffino</i>	
5.1	Introduction	107
5.2	Ubiquitin-independent Proteasome Substrates	109

5.2.1	Ornithine Decarboxylase	109
5.2.2	p21 ^{Waf1/Cip1}	110
5.2.3	Retinoblastoma Protein	111
5.2.4	p53 and p73	111
5.2.5	Human Thymidylate Synthase	112
5.2.6	Rpn4	112
5.2.7	NF- κ B and I κ B α	113
5.2.8	Steroid Receptor Co-activator-3	114
5.2.9	c-Jun	114
5.3	Mechanisms of Ubiquitin-independent Degradation	115
5.4	Conclusion	118
6	Endoplasmic Reticulum Protein Quality Control and Degradation	123
	<i>Antje Schäfer, Zlatka Kostova and Dieter H. Wolf</i>	
6.1	Introduction	123
6.2	ER-import, Folding and the Unfolded Protein Response	124
6.3	General Principles and Components of ERQD (Endoplasmic Reticulum Quality Control and Protein Degradation)	126
6.4	Mechanism of ERQD	127
6.5	"Overflow" Degradation Pathways: ER-to-Golgi Transport and Autophagocytosis	131
6.6	The Retrotranslocation Channel	132
6.7	Metazoan ERQD	133
7	Interactions between Viruses and the Ubiquitin-Proteasome System	145
	<i>Jessica M. Boname and Paul J. Lehner</i>	
7.1	Introduction	145
7.2	Overview of Viruses and the Ubiquitin-Proteasome System	146
7.2.1	Proteolysis	146
7.2.2	Viruses and the ERAD Pathway	146
7.2.3	Membrane Protein Trafficking and Endosomal Sorting	147
7.2.4	Viral Entry and Egress	148
7.2.5	Transcriptional Regulation	149
7.2.6	Cell Cycle Control	149
7.2.7	Cell Signaling	150
7.3	Viruses and E3 Ubiquitin-Protein Ligases	151
7.3.1	ICP0 – A Viral RING E3 Ligase in HSV Activation	152
7.3.2	Preventing the Release of Interferon	153
7.3.3	Viral E3 Ligases Ubiquitinate and Dispose of Critical Immune Receptors	154
7.3.4	Degradation of MHC Class I Molecules by the mK3 Protein of MHV-68 Virus	154
7.3.5	Degradation of Immunoreceptors by Kaposi's Sarcoma-associated Herpesvirus	155
7.3.6	Viral SCF E3 Ligases	156
7.3.7	HIV Vif and APOBEC Function	157

7.3.8	Viral Recruitment of E3 Ligases	158
7.4	Conclusions	159
8	The Ubiquitin-Proteasome System in Parkinson's Disease	169
	<i>Kevin St. P. McNaught</i>	
8.1	Introduction	169
8.2	Protein Handling in the CNS	172
8.3	The UPS and Protein Mishandling in PD	173
8.4	Parkin	173
8.5	UCH-L1	175
8.6	α -Synuclein	175
8.7	Dardarin/LRRK2	177
8.8	PINK1	178
8.9	DJ-1	179
8.10	Proteasomal Dysfunction in Sporadic PD	180
8.10.1	Altered Proteasomal Function	180
8.10.2	Role of Proteasomal Dysfunction in the Neurodegenerative Process	181
8.10.3	The Cause of Proteasomal Dysfunction	183
8.11	Conclusion	184
9	The Molecular Pathway to Neurodegeneration in Parkin-Related Parkinsonism	195
	<i>Ryosuke Takahashi</i>	
9.1	Introduction	195
9.2	Parkin is an E3 Ubiquitin Ligase	196
9.2.1	Parkin and the Ubiquitin-Proteasome System	196
9.2.2	Proteasome-independent Role of Parkin	197
9.2.3	Multiple Monoubiquitination is Mediated by Parkin	197
9.2.4	Modulators of Parkin E3 Activity	198
9.3	Substrates of Parkin	199
9.3.1	Parkin Substrates and their Recognition Mechanisms	199
9.3.2	The Link between Substrate Accumulation and Cell Death: Pael-R	201
9.3.2.1	Pael-R and Endoplasmic Reticulum Stress	201
9.3.2.2	Pael-R Overexpressing Animals and Dopaminergic Neurodegeneration	202
9.3.3	The Link between Substrate Accumulation and Cell Death: CDC-rel1, Synphilin-1, Cyclin E and p38	203
9.4	The Animal Models of AR-JP	203
9.4.1	Drosophila Model of AR-JP	203
9.4.2	Parkin-null Drosophila and Drosophila	204
9.4.3	Mouse Model of AR-JP	204
9.4.4	The Problems with Animal Models of AR-JP	205
9.5	Future Directions	205

10	Parkin and Neurodegeneration	211
	<i>Sathya R. Sriram, Valina L. Dawson and Ted M. Dawson</i>	
10.1	Introduction	211
10.2	AR JP and Parkin	212
10.2.1	ARJP: Introduction	212
10.2.2	<i>PARKIN</i> : The Gene	213
10.2.3	<i>PARKIN</i> : Localization and Regulation	215
10.3	Parkin in the Ubiquitin-Proteasome Pathway	216
10.3.1	The Ubiquitin-Proteasome Pathway	216
10.3.2	<i>PARKIN</i> : An E3 Ubiquitin Ligase	217
10.3.3	Parkin and Lewy Bodies	218
10.3.4	Parkin Substrates	218
10.4	Parkin in Neuroprotection	221
10.4.1	Toxic Parkin Substrates	221
10.4.2	Stress-mediated Toxicity	222
10.5	Parkin and Other PD-linked Genes	223
10.5.1	α -Synuclein	223
10.5.2	DJ-1	224
10.5.3	LRRK2	224
10.6	Mechanisms of Parkin Dysfunction	225
10.6.1	Pathogenic Mutations	225
10.6.2	Cellular Regulators of Parkin	226
10.6.3	Post-translational Regulation of Parkin	226
10.7	Animal Models of Parkin Deficiency	227
10.7.1	<i>Drosophila</i> Models	227
10.7.2	Mouse Models	228
10.8	Concluding Remarks	228

Index	237
--------------	------------